Article
Refine
Year of publication
- 2012 (128) (remove)
Document Type
- Article (128) (remove)
Keywords
- (Bio)degradation (1)
- 802.15.4 (1)
- Acceleration (1)
- Afterload (1)
- Alginate beads (1)
- Anastomotic leakage (1)
- Aufschlagversuch (1)
- Autolysis (1)
- Avalanche (1)
- Bank-issued Warrants (1)
- Bluetooth (1)
- Borehole heat exchanger (1)
- Calorimetric gas sensor (1)
- Cell permeability (1)
- CellDrum (1)
- Cellular force (1)
- Chemical imaging sensor (1)
- Circular Dichroism (1)
- Compliance (1)
- Consensus (1)
Institute
- Fachbereich Medizintechnik und Technomathematik (41)
- Fachbereich Wirtschaftswissenschaften (26)
- INB - Institut für Nano- und Biotechnologien (25)
- Fachbereich Chemie und Biotechnologie (15)
- Fachbereich Elektrotechnik und Informationstechnik (14)
- IfB - Institut für Bioengineering (14)
- Fachbereich Maschinenbau und Mechatronik (11)
- Fachbereich Bauingenieurwesen (5)
- Fachbereich Energietechnik (5)
- Fachbereich Architektur (3)
- Fachbereich Luft- und Raumfahrttechnik (3)
- Sonstiges (3)
- Solar-Institut Jülich (2)
- Fachbereich Gestaltung (1)
- Freshman Institute (1)
- Nowum-Energy (1)
Persistent infection with high-risk human papillomaviruses (hrHPV) can result in the formation of anogenital cancers. As hrHPV proteins E6 and E7 are required for cancer initiation and maintenance, they are ideal targets for immunotherapeutic interventions. Previously, we have described the development of DNA vaccines for the induction of HPV16 E6 and E7 specific T cell immunity. These vaccines consist of ‘gene-shuffled’ (SH) versions of HPV16 E6 and E7 that were fused to Tetanus Toxin Fragment C domain 1 (TTFC) and were named TTFC-E6SH and TTFC-E7SH. Gene-shuffling was performed to avoid the risk of inducing malignant transformation at the vaccination site. Here, we describe the preclinical safety evaluation of these candidate vaccines by analysis of their transforming capacity in vitro using established murine fibroblasts (NIH 3T3 cells) and primary human foreskin keratinocytes (HFKs). We demonstrate that neither ectopic expression of TTFC-E6SH and TTFC-E7SH alone or in combination enabled NIH 3T3 cells to form colonies in soft agar. In contrast, expression of HPV16 E6WT and E7WT alone or in combination resulted in effective transformation. Similarly, retroviral transduction of HFKs from three independent donors with both TTFC-E6SH and TTFC-E7SH alone or in combination did not show any signs of immortalization. In contrast, the combined expression of E6WT and E7WT induced immortalization in HFKs from all donors. Based on these results we consider it justified to proceed to clinical evaluation of DNA vaccines encoding TTFC-E6SH and TTFC-E7SH in patients with HPV16 associated (pre)malignancies.